Citable filing context
DVA's research view summarizes recent SEC filing context, starting with earnings from Aug 4, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 4, 2026 | earnings | DaVita Inc. reported Q2 2026 revenue of $3.554 billion and diluted earnings per share of $4.02. |
| Jun 8, 2026 | debt_offering | DaVita Inc. entered into a credit agreement amendment for an incremental $500 million term loan. |
| Feb 2, 2026 | earnings | DaVita Inc. reported Q4 2025 revenue of $3.62 billion and full-year 2025 revenue of $13.64 billion. |
| Aug 4, 2026 | Guidance: adjusted_diluted_net_income_per_share | 14.10 to 15.20 |
| Aug 4, 2026 | Guidance: adjusted_operating_income | 2150.00 to 2250.00 |
| Aug 4, 2026 | Guidance: free_cash_flow | 1000.00 to 1250.00 |
| Aug 4, 2026 | mda_quarterly | DaVita’s financial performance in the second quarter of 2026 reflects growth in treatment volumes, which rose 2.8% sequentially, driven by higher patient census and lower-than-expected mortality. While U.S. dialysis revenue per treatment saw a slight sequential decline due to payor mix fluctuations, year-to-date revenue per treatment increased 3.6% compared to 2025, bolstered by Medicare rate adjustments. Operating income for the U.S. dialysis segment grew 6.3% sequentially, benefiting from improved labor productivity and lower pharmaceutical costs, specifically regarding phosphate binders. The company’s ancillary services, particularly Integrated Kidney Care (IKC), showed significant improvement, swinging to an operating profit of $40 million in the second quarter from a loss in the first, primarily due to increased shared savings. Conversely, international operations faced headwinds from divestiture-related losses. Key risks remain centered on labor market volatility, including ongoing union organizing activities and wage inflation, alongside potential reimbursement pressures from commercial payor contract negotiations and the expiration of enhanced Affordable Care Act premium tax credits. DaVita maintains a stable liquidity position, supported by $1.4 billion in available revolving credit, and continues to prioritize capital allocation through share repurchases and strategic investments in middle-molecule clearance therapies like expanded hemodialysis. |
| May 5, 2026 | mda_quarterly | DaVita reported Q1 2026 consolidated revenues of $3.4 billion, a 5.6% sequential decrease but a 6.0% increase year-over-year. U.S. dialysis operating income fell 9.0% sequentially to $506 million, reflecting seasonal declines in co-insurance and deductibles, though average reimbursement rates rose year-over-year due to Medicare base rate adjustments. Patient care costs per treatment increased, driven by higher wage rates and insurance costs. Ancillary services, specifically Integrated Kidney Care (IKC), experienced a sharp sequential operating income decline to $6 million, primarily due to a net decrease in shared savings. Key operational risks include the lingering effects of a 2025 cybersecurity incident on billing cycles, the impact of the One Big Beautiful Bill Act (OBBBA), and rising union organizing activities in California. Internationally, the company expanded its footprint to 596 centers across 14 countries. Liquidity remains robust with $1.125 billion available on its revolving credit facility, and the company allocated $396 million toward share repurchases. Free cash flow improved to $140 million from a $45 million deficit in Q1 2025, supported by better working capital management and reduced capital expenditures. |
Source: SEC EDGAR filing text and events; period Aug 4, 2026; filed Aug 4, 2026.
DVA company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.